Mr. Jenne is Ionis’ executive vice president, chief global product strategy officer. He has more than 25 years of biopharmaceutical experience launching and commercializing innovative medicines in the U.S. and globally. He has broad relevant experience in rare, specialty and common diseases across therapeutic areas including cardiovascular, neurology and allergy.
Mr. Jenne leads all aspects of commercialization including marketing, sales, commercial operations, market access and patient services. He also oversees Ionis’ portfolio planning, market insights and medical affairs functions.
Before rejoining Ionis in 2024, Mr. Jenne previously spent five years in senior commercial leadership roles at Ionis and Akcea, which was fully acquired by Ionis in 2020. During his time at Ionis and Akcea, Mr. Jenne built commercial capabilities in many of Ionis’ key disease areas including transthyretin-mediated amyloidosis and familial chylomicronemia syndrome. Earlier in his career, Mr. Jenne held commercial roles for companies including Schering Plough, King Pharmaceuticals, Acorda Therapeutics and Praecis Pharmaceuticals. Mr. Jenne holds a BS in Marketing from Arizona State University.